CAR-T Cell Development for Cutaneous T Cell Lymphoma: Current Limitations and Potential Treatment Strategies

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Sep 5

PMID 36059451

Authors

Van To

Vera J Evtimov

Graham Jenkin

Aleta Pupovac

Alan O Trounson

Richard L Boyd

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited. Barriers to effective CAR-T cell therapy in treating CTCL include T cell aplasia in autologous transplants, CAR-T product contamination with leukemic T cells, CAR-T fratricide (when the target antigen is present on normal T cells), and tumor heterogeneity. To address these critical challenges, innovative CAR engineering by targeting multiple antigens to strike a balance between efficacy and safety of the therapy is necessary. In this review, we discuss the current obstacles to CAR-T cell therapy and highlight potential targets in treating CTCL. Looking forward, we propose strategies to develop more powerful dual CARs that are advancing towards the clinic in CTCL therapy.

Citing Articles

Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma.

Chinas N, Kaliampou S, Nikolaou V Curr Oncol Rep. 2025; .

PMID: 40055269 DOI: 10.1007/s11912-025-01646-6.

Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).

Case K, Allen P Curr Hematol Malig Rep. 2025; 20(1):5.

PMID: 39800801 DOI: 10.1007/s11899-024-00746-7.

T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas.

Willscher E, Schultheiss C, Paschold L, Lea Schumann F, Schmidt-Barbo P, Thiele B Haematologica. 2024; 110(2):457-469.

PMID: 39219501 PMC: 11788643. DOI: 10.3324/haematol.2024.285395.

The potential role of CD8+ cytotoxic T lymphocytes and one branch connected with tissue-resident memory in non-luminal breast cancer.

Zhao Z, Ma X, Cai Z PeerJ. 2024; 12:e17667.

PMID: 39006029 PMC: 11246025. DOI: 10.7717/peerj.17667.

Immune landscape and response to oncolytic virus-based immunotherapy.

Lin C, Teng W, Tian Y, Li S, Xia N, Huang C Front Med. 2024; 18(3):411-429.

PMID: 38453818 DOI: 10.1007/s11684-023-1048-0.

References

Hege K, Bergsland E, Fisher G, Nemunaitis J, Warren R, McArthur J . Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017; 5:22. PMC: 5360066. DOI: 10.1186/s40425-017-0222-9. View

Nicolet C, Siegel D, Surfus J, Sondel P . TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines. Tumour Biol. 1997; 18(6):356-66. DOI: 10.1159/000218050. View

Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D . Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503. PMC: 6511988. DOI: 10.1038/s41591-018-0201-9. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

Duarte R, Canals C, Onida F, Gabriel I, Arranz R, Arcese W . Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010; 28(29):4492-9. DOI: 10.1200/JCO.2010.29.3241. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J . Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A. 2006; 103(12):4586-91. PMC: 1450215. DOI: 10.1073/pnas.0505379103. View

Kim Y, Bagot M, Pinter-Brown L, Rook A, Porcu P, Horwitz S . Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19(9):1192-1204. DOI: 10.1016/S1470-2045(18)30379-6. View

Kim Y, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A . Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007; 109(11):4655-62. DOI: 10.1182/blood-2006-12-062877. View

10.

DAmbrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, Mantovani A . Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol. 1998; 161(10):5111-5. View

11.

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

12.

Chmielewski M, Hombach A, Heuser C, Adams G, Abken H . T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004; 173(12):7647-53. DOI: 10.4049/jimmunol.173.12.7647. View

13.

Rappl G, Abken H, Muche J, Sterry W, Tilgen W, Andre S . CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death. Leukemia. 2002; 16(5):840-5. DOI: 10.1038/sj.leu.2402438. View

14.

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View

15.

Golubovskaya V, Berahovich R, Zhou H, Xu S, Harto H, Li L . CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. Cancers (Basel). 2017; 9(10). PMC: 5664078. DOI: 10.3390/cancers9100139. View

16.

Genega E, Hutchinson B, Reuter V, Gaudin P . Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000; 13(11):1186-91. DOI: 10.1038/modpathol.3880220. View

17.

Ni X, Jorgensen J, Goswami M, Challagundla P, Decker W, Kim Y . Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome. Clin Cancer Res. 2014; 21(2):274-85. DOI: 10.1158/1078-0432.CCR-14-0830. View

18.

van Doorn R, van Kester M, Dijkman R, Vermeer M, Mulder A, Szuhai K . Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood. 2008; 113(1):127-36. DOI: 10.1182/blood-2008-04-153031. View

19.

Bruijnzeel P, Mudde G, Versluis C, van Ieperen-van Dijk A, Bihari I, Knol E . Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions. J Allergy Clin Immunol. 2000; 105(5):1008-16. DOI: 10.1067/mai.2000.106544. View

20.

Yang Y, Jacoby E, Fry T . Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol. 2015; 22(6):509-515. PMC: 4636084. DOI: 10.1097/MOH.0000000000000181. View